Alain Baron (L), Escient CEO and Marcus Boehm, Escient CSO
Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates
A little over two years after emerging from stealth, Escient Pharmaceuticals is back Monday with a new fundraising round and their first clinical trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.